Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011)

Biogen (BIIB) posted quarterly Current Deferred Tax Assets of $8.1 million for Q4 2011, down 92.78% year-over-year from $112.2 million in Q4 2010, and down 92.78% on a QoQ basis from $112.2 million in Q4 2010.

Biogen (BIIB) Current Deferred Tax Assets (2010 - 2011) Analysis & Trends

Biogen (BIIB) has reported Current Deferred Tax Assets for 2 consecutive years, with $8.1 million the latest figure, recorded in Q4 2011.

  • In Q4 2011, Current Deferred Tax Assets fell 92.78% year-over-year to $8.1 million; the TTM figure through Dec 2011 stood at $8.1 million (down 92.78% YoY), while the FY2011 annual figure was $8.1 million, down 92.78% from the prior year.
  • Current Deferred Tax Assets came in at $8.1 million for Q4 2011 at Biogen, down from $112.2 million in the prior quarter.
  • The five-year high for Current Deferred Tax Assets was $112.2 million in Q4 2010, with the low at $8.1 million in Q4 2011.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Dec 31, 2011 8.10 Mn
Dec 31, 2011 8.10 Mn
Dec 31, 2010 112.20 Mn
Dec 31, 2010 112.20 Mn